Zealand Pharma A/S

299 articles about Zealand Pharma A/S

• Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

  12/16/2021

  Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 TrialAssessing Glepaglutide in Patients with Short Bowel Syndrome

• Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital

  12/14/2021

  Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital Agreement includes an upfront payment of $100 million,

• Zealand Pharma to Participate in Jefferies London Healthcare Conference

  11/12/2021

  Zealand Pharma to Participate in Jefferies London Healthcare Conference Copenhagen, DK and Boston, MA, U.S. November 12 , 2021

• Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (CHI)

  11/5/2021

  Zealand Pharma today announced that it has entered into definitive collaboration agreements with DEKA Research & Development Corp., to develop a continuous infusion pump to be used in combination with dasiglucagon, an investigational agent currently in phase 3 trials in patients with congenital hyperinsulinism.

• Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021

  11/4/2021

  Zealand Pharma A/S a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced that it will host a conference call on November 11, 2021 at 4 pm CET following the announcement of results for the third quarter of 2021.

• Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting

  11/1/2021

  Zealand Pharma A/S today announced it will present preclinical data from its amylin analogue, ZP8396 at the Obesity Society Annual Meeting, to be held virtually during ObesityWeek® Interactive, an online conference taking place in the week of November 1-5, 2021.

• Total number of shares and voting rights in Zealand Pharma at September 30, 2021

  9/30/2021

  Zealand Pharma A/S announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.

• Zealand Pharma increases its share capital as a consequence of exercise of employee warrants - Sep 10, 2021

  9/10/2021

  Zealand Pharma A/S, a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 30,748 divided into 30,748 new shares with a nominal value of DKK 1 each.

• Zealand Pharma Presents Data at 2021 ESPEN Virtual Congress Demonstrating Dose-dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models – in Contrast to Short-acting GLP-2

  9/9/2021

  Zealand Pharma today announced it will present four posters at the 2021 European Society for Clinical Nutrition and Metabolism (ESPEN) Virtual Congress, which is being held September 9-14, 2021.

• New Employee Elected Director to the board of Zealand Pharma A/S

  9/1/2021

  Zealand Pharma A/S . Anneline Nansen has been instated as an employee elected member of the Board of Directors of Zealand effective as of 1 September 2021.

• Employee Elected Director to step down from the board of Zealand Pharma A/S

  8/13/2021

  Zealand Pharma A/S . Gertrude Koefoed Rasmussen an employee elected member of the Board of Zealand will step down from her position on the board effective as of 31 August 2021 and leave Zealand to take up an offer of employment at another company.

• Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas

  8/12/2021

  Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas

• Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma

  8/10/2021

   Protagonist Therapeutics, Inc. today announced it has resolved its Collaboration Agreement dispute with Zealand Pharma by reducing future development and sales milestone payments and royalties owed to Zealand for Protagonist's product candidate rusfertide under the companies' 2012 Collaboration Agreement.

• Zealand Pharma Hosts Conference Call on August 12 at 4 pm CET (10am ET) to Present Second Quarter Results for 2021

  8/5/2021

  Zealand Pharma A/S a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced that it will host a conference call on August 12, 2021 at 4 pm CET following the announcement of results for the second quarter of 2021.

• Zealand Pharma A/S – Final Transactions Under Share Repurchase Program

  7/27/2021

  Copenhagen, DK,27 July 2021 - On June 29, 2021, Zealand Pharma A/S initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission Delegated Regulation 2016/1052 of 8 March 2016.

• Zealand Pharma A/S – Transaction Under Share Repurchase Program - July 20, 2021

  7/20/2021

  Copenhagen, DK and Boston, MA, 20 July 2021 - On June 29, 2021, Zealand Pharma A/S initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission Delegated Regulation 2016/1052 of 8 March 2016.

• Zealand Pharma A/S – Transaction Under Share Repurchase Program

  7/13/2021

  Zealand Pharma A/S initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission Delegated Regulation 2016/1052 of 8 March 2016.

• Zealand Pharma A/S - Transactions Under Share Repurchase Program

  7/6/2021

  Zealand Pharma A/S initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission Delegated Regulation 2016/1052 of 8 March 2016.

• Total number of shares and voting rights in Zealand Pharma at June 30, 2021

  6/30/2021

  Copenhagen, DK and Boston, MA,June 30, 2021– Zealand Pharma A/S, a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.

• Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)

  6/29/2021

  Zealand Pharma A/S a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced it will present three posters at the upcoming 17th Congress of the Intestinal Rehabilitation and Transplantation Association, which is being held both virtually and in Auckland, New Zealand June 30-July 2, 2021.